Nascent Biotech (Nascent Biotech) Cash And Cash Equivalents : $0.62 Mil (As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

What is Nascent Biotech Cash And Cash Equivalents?

Nascent Biotech's quarterly cash and cash equivalents increased from Jun. 2023 ($0.01 Mil) to Sep. 2023 ($1.00 Mil) but then stayed the same from Sep. 2023 ($1.00 Mil) to Dec. 2023 ($0.62 Mil).

Nascent Biotech's annual cash and cash equivalents increased from Mar. 2021 ($0.00 Mil) to Mar. 2022 ($0.09 Mil) and increased from Mar. 2022 ($0.09 Mil) to Mar. 2023 ($0.17 Mil).

Nascent Biotech Cash And Cash Equivalents Historical Data

The historical data trend for Nascent Biotech's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nascent Biotech Cash And Cash Equivalents Chart

Nascent Biotech Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Cash And Cash Equivalents

Get a 7-Day Free Trial

0.13

0.09

0.17

Nascent Biotech Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash And Cash Equivalents	Get a 7-Day Free Trial															0.56	0.17	0.01	1.00	0.62

Nascent Biotech Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Nascent Biotech (OTCPK:NBIO) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Nascent Biotech Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Nascent Biotech's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Nascent Biotech (Nascent Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nascent Biotech Inc (OTCPK:NBIO) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

631 US Hwy 1, Suite 407, N Palm Beach, FL, USA, 33408

Website

https://www.nascentbiotech.com

Nascent Biotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is focused on the development and delivery of human antibodies and cytokine responses to the treatment of cancer. The company's products include Pritumumab, CLNH5, and MultiPharm. The company is actively engaged in the development of Pritumumab which would be used for the treatment of brain cancer and pancreatic cancer. The company is also exploring the use of Pritumumab against other viruses.

Executives

Lowell Thomas Holden	director, officer: CFO	631 US HWY 1, SUITE 407, NORTH PALM BEACH FL 33408
Sean Carrick	director, officer: President	631 US HWY 1, SUITE 407, NORTH PALM BEACH FL 33408
Brandon Price	director, officer: Senior VP Business Development	6330 NANCY RIDGE DR., SUITE 105, SAN DIEGO CA 92121
Douglas John Karas	director	631 US HWY 1, SUITE 407, NORTH PALM BEACH FL 33408
Mark Glassy	director, officer: CEO	6330 NANCY RIDGE DR., SUITE 105, SAN DIEGO CA 92121